Australia's most trusted
source of pharma news
Posted 23 October 2025 AM
Novo Nordisk Chair Helge Lund, Vice-chair Henrik Poulsen and five other independent board members will step down next month following a dispute with the Novo Nordisk Foundation over proposed changes to the board.
The non-profit foundation, which is Novo’s majority shareholder, with 77 per cent of voting rights and 28 per cent of shares, will put forward current foundation Chair and former Novo CEO Lars Rebien Sorensen as the new Chair of the Novo board, and current Novonesis chair Cees de Jong as Novo’s Vice-chair, at an extraordinary general meeting on November 14.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.